3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
7
Neoplasms
4
Advanced Cancer
4
Lymphoma, Non-Hodgkin
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Various Advanced Cancer
1
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Melanoma, Cutaneous Malignant
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
80
Nivolumab
60
Sunitinib
59
Sorafenib
36
Everolimus
32
pazopanib
30
Axitinib
27
cabozantinib
25
Ipilimumab
24
Bevacizumab
24
atezolizumab
20
belzutifan
19
lenvatinib
16
avelumab
13
Paclitaxel
10
Docetaxel
9
temsirolimus
8
Cyclophosphamide
8
spartalizumab
7
fludarabine
7
Interleukin-2
7
Interferon alpha-2
7
tivozanib
6
durvalumab
6
Cetuximab
6
cemiplimab
5
aldesleukin
5
Ramucirumab
5
CB-839
5
bempegaldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Renal Cell
×
relatlimab
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled